BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30093084)

  • 1. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
    Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
    Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    Stevenson HL; Prats MM; Sasatomi E
    BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibility of chemotherapy-related liver injury.
    Vigano L; De Rosa G; Toso C; Andres A; Ferrero A; Roth A; Sperti E; Majno P; Rubbia-Brandt L
    J Hepatol; 2017 Jul; 67(1):84-91. PubMed ID: 28284915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
    Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
    Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
    Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
    Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular Regenerative Hyperplasia in Patients Undergoing Liver Resection for Colorectal Metastases After Chemotherapy: Risk Factors, Preoperative Assessment and Clinical Impact.
    Viganò L; Rubbia-Brandt L; De Rosa G; Majno P; Langella S; Toso C; Mentha G; Capussotti L
    Ann Surg Oncol; 2015 Dec; 22(13):4149-57. PubMed ID: 25845431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
    Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
    Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
    Robinson SM; Mann DA; Manas DM; Oakley F; Mann J; White SA
    Br J Cancer; 2013 Oct; 109(9):2396-403. PubMed ID: 24113143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test.
    Russolillo N; Langella S; Perotti S; Lo Tesoriere R; Forchino F; Ferrero A
    Int J Surg; 2016 Jul; 31():80-5. PubMed ID: 27260311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
    Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
    Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
    Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
    J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
    Khan AZ; Morris-Stiff G; Makuuchi M
    J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.
    Brouquet A; Benoist S; Julie C; Penna C; Beauchet A; Rougier P; Nordlinger B
    Surgery; 2009 Apr; 145(4):362-71. PubMed ID: 19303984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
    Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
    HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.